JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells

Oncogene

Volumn 33, Issue 9, 2014, Pages 1148-1157

  Walters, Z S ^a   Villarejo Balcells, B ^a   Olmos, D ^a,b   Buist, T W S ^a   Missiaglia, E ^a,c   Allen, R ^a   Al Lazikani, B ^a   Garrett, M D ^a   Blagg, J ^a   Shipley, J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

histone methylation; JARID2; myogenic differentiation; PAX3 FOXO1; polycomb repressive complex 2; rhabdomyosarcoma

Indexed keywords

HISTONE DEMETHYLASE; HISTONE H3; HYBRID PROTEIN; LYSINE; MESSENGER RNA; MYOGENIN; MYOSIN LIGHT CHAIN; PAX3 FOXO1 FUSION PROTEIN; POLYCOMB REPRESSIVE COMPLEX 2; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR PAX3; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; CELL VIABILITY ASSAY; CHILD; CONTROLLED STUDY; FUSION GENE; GENE; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; HISTONE METHYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; JARID2 GENE; MAJOR CLINICAL STUDY; METASTASIS; MUSCLE DEVELOPMENT; NUCLEOTIDE SEQUENCE; PAX7 FOXO1 FUSION GENE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA; SARCOMA CELL;

CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEMETHYLASES; HUMANS; MUSCLE DEVELOPMENT; MYOGENIN; NUCLEAR PROTEINS; ONCOGENE PROTEINS, FUSION; PAIRED BOX TRANSCRIPTION FACTORS; POLYCOMB REPRESSIVE COMPLEX 2; PROMOTER REGIONS, GENETIC; RHABDOMYOSARCOMA; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 84896691188     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.46     Document Type: Article

References (50)

1. Davicioni E, Finckenstein FG, Shahbazian V, Buckley JD, Triche TJ, Anderson MJ. Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. Cancer Res 2006; 66: 6936-6946.
2. Davicioni E, Anderson MJ, Finckenstein FG, Lynch JC, Qualman SJ, Shimada H et al. Molecular classification of rhabdomyosarcoma-genotypic and phenotypic determinants of diagnosis: A report from the Children's Oncology Group. Am J Pathol 2009; 174: 550-564.
3. Missiaglia E, Williamson D, Chisholm J, Wirapati P, Pierron G, Petel F et al. PAX3/ FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. J Clin Oncol 2012; 30: 1670-1677.
4. Sorensen PH, Lynch JC, Qualman SJ, Tirabosco R, Lim JF, Maurer HM et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: A report from the children's oncology group. J Clin Oncol 2002; 20: 2672-2679.
5. Bennicelli JL, Edwards RH, Barr FG. Mechanism for transcriptional gain of function resulting from chromosomal translocation in alveolar rhabdomyosarcoma. Proc Natl Acad Sci USA 1996; 93: 5455-5459.
6. Epstein JA, Song B, Lakkis M, Wang C. Tumor-specific PAX3-FKHR transcription factor, but not PAX3, activates the platelet-derived growth factor alpha receptor. Mol Cell Biol 1998; 18: 4118-4130.
7. Fredericks WJ, Galili N, Mukhopadhyay S, Rovera G, Bennicelli J, Barr FG et al. The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3. Mol Cell Biol 1995; 15: 1522-1535.
8. Zhang L, Wang C. Identification of a new class of PAX3-FKHR target promoters: A role of the Pax3 paired box DNA binding domain. Oncogene 2007; 26: 1595-1605.
9. Kikuchi K, Tsuchiya K, Otabe O, Gotoh T, Tamura S, Katsumi Y et al. Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcoma. Biochem Biophys Res Commun 2008; 365: 568-574.
10. Cao L, Yu Y, Bilke S, Walker RL, Mayeenuddin LH, Azorsa DO et al. Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. Cancer Res 2010; 70: 6497-6508.
11. Calhabeu F, Hayashi S, Morgan JE, Relaix F, Zammit PS. Alveolar rhabdomyosarcoma-Associated proteins PAX3/FOXO1A and PAX7/FOXO1A suppress the transcriptional activity of MyoD-Target genes in muscle stem cells. Oncogene 2013; 32: 651-662.
12. Cloos PA, Christensen J, Agger K, Helin K. Erasing the methyl mark: Histone demethylases at the center of cellular differentiation and disease. Genes Dev 2008; 22: 1115-1140.
13. Lu PJ, Sundquist K, Baeckstrom D, Poulsom R, Hanby A, Meier-Ewert S et al. A novel gene (PLU-1) containing highly conserved putative DNA/chromatin binding motifs is specifically up-regulated in breast cancer. J Biol Chem 1999; 274: 15633-15645.
14. Xiang Y, Zhu Z, Han G, Ye X, Xu B, Peng Z et al. JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer. Proc Natl Acad Sci USA 2007; 104: 19226-19231.
15. Schildhaus HU, Riegel R, Hartmann W, Steiner S, Wardelmann E, Merkelbach-Bruse S et al. Lysine-specific demethylase 1 is highly expressed in solitary fibrous tumors, synovial sarcomas, rhabdomyosarcomas, desmoplastic small round cell tumors, and malignant peripheral nerve sheath tumors. Hum Pathol 2011; 42: 1667-1675.
16. Schulte JH, Lim S, Schramm A, Friedrichs N, Koster J, Versteeg R et al. Lysinespecific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: Implications for therapy. Cancer Res 2009; 69: 2065-2071.
17. Lee MH, Jothi M, Gudkov AV, Mal AK. Histone methyltransferase KMT1A restrains entry of alveolar rhabdomyosarcoma cells into a myogenic differentiated state. Cancer Res 2011; 71: 3921-3931.
18. Asp P, Blum R, Vethantham V, Parisi F, Micsinai M, Cheng J et al. Genome-wide remodeling of the epigenetic landscape during myogenic differentiation. Proc Natl Acad Sci USA 2011; 108: E149-E158.
19. Landeira D, Sauer S, Poot R, Dvorkina M, Mazzarella L, Jorgensen HF et al. Jarid2 is a PRC2 component in embryonic stem cells required for multi-lineage differentiation and recruitment of PRC1 and RNA Polymerase II to developmental regulators. Nat Cell Biol 2010; 12: 618-624.
20. Shen X, Kim W, Fujiwara Y, Simon MD, Liu Y, Mysliwiec MR et al. Jumonji modulates polycomb activity and self-renewal versus differentiation of stem cells. Cell 2009; 139: 1303-1314.
21. Juan AH, Derfoul A, Feng X, Ryall JG, Dell'Orso S, Pasut A et al. Polycomb EZH2 controls self-renewal and safeguards the transcriptional identity of skeletal muscle stem cells. Genes Dev 2011; 25: 789-794.
22. Klose RJ, Kallin EM, Zhang Y. JmjC-domain-containing proteins and histone demethylation. Nat Rev Genet 2006; 7: 715-727.
23. Pasini D, Cloos PA, Walfridsson J, Olsson L, Bukowski JP, Johansen JV et al. JARID2 regulates binding of the polycomb repressive complex 2 to target genes in ES cells. Nature 2010; 464: 306-310.
24. Chang CJ, Hung MC. The role of EZH2 in tumour progression. Br J Cancer 2012; 106: 243-247.
25. Kim TG, Chen J, Sadoshima J, Lee Y. Jumonji represses atrial natriuretic factor gene expression by inhibiting transcriptional activities of cardiac transcription factors. Mol Cell Biol 2004; 24: 10151-10160.
26. Li G, Margueron R, Ku M, Chambon P, Bernstein BE, Reinberg D. Jarid2 and PRC2, partners in regulating gene expression. Genes Dev 2010; 24: 368-380.
27. Peng JC, Valouev A, Swigut T, Zhang J, Zhao Y, Sidow A et al. Jarid2/Jumonji coordinates control of PRC2 enzymatic activity and target gene occupancy in pluripotent cells. Cell 2009; 139: 1290-1302.
28. Williamson D, Missiaglia E, de Reynies A, Pierron G, Thuille B, Palenzuela G et al. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. J Clin Oncol 2010; 28: 2151-2158.
29. Charytonowicz E, Cordon-Cardo C, Matushansky I, Ziman M. Alveolar rhabdomyosarcoma: Is the cell of origin a mesenchymal stem cell? Cancer Lett 2009; 279: 126-136.
30. Aguanno S, Bouche M, Adamo S, Molinaro M. 12-O-Tetradecanoylphorbol-13- Acetate-induced differentiation of a human rhabdomyosarcoma cell line. Cancer Res 1990; 50: 3377-3382.
31. Linardic CM. PAX3-FOXO1 fusion gene in rhabdomyosarcoma. Cancer Lett 2008; 270: 10-18.
32. Stojic L, Jasencakova Z, Prezioso C, Stutzer A, Bodega B, Pasini D et al. Chromatin regulated interchange between polycomb repressive complex 2 (PRC2)-Ezh2 and PRC2-Ezh1 complexes controls myogenin activation in skeletal muscle cells. Epigenet Chromatin 2011; 4: 16.
33. Tonelli R, McIntyre A, Camerin C, Walters ZS, Di Leo K, Selfe J et al. Antitumor activity of sustained N-myc reduction in rhabdomyosarcomas and transcriptional block by antigene therapy. Clin Cancer Res 2012; 18: 796-807.
34. Shen X, Liu Y, Hsu YJ, Fujiwara Y, Kim J, Mao X et al. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol Cell 2008; 32: 491-502.
35. Xia SJ, Holder DD, Pawel BR, Zhang C, Barr FG. High expression of the PAX3-FKHR oncoprotein is required to promote tumorigenesis of human myoblasts. Am J Pathol 2009; 175: 2600-2608.
36. Lollini PL, De Giovanni C, Landuzzi L, Nicoletti G, Scotlandi K, Nanni P. Reduced metastatic ability of in vitro differentiated human rhabdomyosarcoma cells. Invasion Metast 1991; 11: 116-124.
37. Merlino G, Helman LJ. Rhabdomyosarcoma-working out the pathways. Oncogene 1999; 18: 5340-5348.
38. Barlow JW, Wiley JC, Mous M, Narendran A, Gee MF, Goldberg M et al. Differentiation of rhabdomyosarcoma cell lines using retinoic acid. Pediatr Blood Cancer 2006; 47: 773-784.
39. Jung J, Kim TG, Lyons GE, Kim HR, Lee Y. Jumonji regulates cardiomyocyte proliferation via interaction with retinoblastoma protein. J Biol Chem 2005; 280: 30916-30923.
40. Kim TG, Kraus JC, Chen J, Lee Y. JUMONJI, a critical factor for cardiac development, functions as a transcriptional repressor. J Biol Chem 2003; 278: 42247-42255.
41. Takeuchi T, Kojima M, Nakajima K, Kondo S. Jumonji gene is essential for the neurulation and cardiac development of mouse embryos with a C3H/He background. Mech Dev 1999; 86: 29-38.
42. Ciarapica R, Russo G, Verginelli F, Raimondi L, Donfrancesco A, Rota R et al. Deregulated expression of miR-26a and Ezh2 in rhabdomyosarcoma. Cell Cycle 2009; 8: 172-175.
43. Richter GH, Plehm S, Fasan A, Rossler S, Unland R, Bennani-Baiti IM et al. EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proc Natl Acad Sci USA 2009; 106: 5324-5329.
44. Palacios D, Summerbell D, Rigby PW, Boyes J. Interplay between DNA methylation and transcription factor availability: Implications for developmental activation of the mouse Myogenin gene. Mol Cell Biol 2010; 30: 3805-3815.
45. Verrier L, Escaffit F, Chailleux C, Trouche D, Vandromme M. A new isoform of the histone demethylase JMJD2A/KDM4A is required for skeletal muscle differentiation. PLoS Genet 2011; 7: E1001390.
46. Grimwade D, Mistry AR, Solomon E, Guidez F. Acute promyelocytic leukemia: A paradigm for differentiation therapy. Cancer Treat Res 2010; 145: 219-235.
47. Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D et al. Long-Term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A children's oncology group study. J Clin Oncol 2009; 27: 1007-1013.
48. Veal GJ, Cole M, Errington J, Pearson AD, Foot AB, Whyman G et al. Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with highrisk neuroblastoma-A study of the United Kingdom Children's Cancer Study Group. Br J Cancer 2007; 96: 424-431.
49. Luo X, Liu Y, Kubicek S, Myllyharju J, Tumber A, Ng S et al. A selective inhibitor and probe of the cellular functions of Jumonji C domain-containing histone demethylases. J Am Chem Soc 2011; 133: 9451-9456.
50. Upadhyay AK, Rotili D, Han JW, Hu R, Chang Y, Labella D et al. An analog of BIX-01294 selectively inhibits a family of histone H3 lysine 9 Jumonji demethylases. J Mol Biol 2012; 416: 319-327.